Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell therapy used in advanced melanoma, and Proleukin, which supports the treatment regimen. The company also advances investigational TIL-based programs for other solid tumors, including cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma. Iovance Biotherapeutics operates as an oncology-focused cell therapy platform, combining manufacturing, clinical development, and commercialization capabilities to deliver personalized immunotherapies for patients with difficult-to-treat cancers. Headquartered in San Carlos, California, it plays a specialized role in the broader biopharmaceutical market by bringing autologous immune-cell therapies into routine clinical use.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Employees

975

Headquarters

San Carlos, CA, United States

Website

www.iovance.com